Study of new ways of supplementary and combinatory therapy of rheumatoid arthritis with immunomodulators. Glucomannan and Imunoglukán ® in adjuvant arthritis
Restricted accessResearch articleFirst published online May, 2009
Study of new ways of supplementary and combinatory therapy of rheumatoid arthritis with immunomodulators. Glucomannan and Imunoglukán ® in adjuvant arthritis
We studied the anti-arthritic activity of glucomannan (GM) isolated from Candida utilis and of Imunoglukán®, a beta-(1,3/1,6)-d-glucan (IMG) isolated from Pleurotus ostreatus. Adjuvant arthritis (AA) was induced intradermally by the injection of Mycobacterium butyricum in incomplete Freund’s adjuvant to Lewis rats. Blood for biochemical and immunological analysis was collected on experimental days 1, 14, 21, and 28. A clinical parameter – hind paw volume (HPV) – was also measured. The detection of IL-1 alpha, IL-4, TNF alpha, and MCP-1 was done by immunoflowcytometry. On day 28 – the end of the experiment – we determined spectrophotometrically: the total anti-oxidant status (TAS) of plasma samples along with thiobarbituric acid-reacting substances (TBARS) levels in plasma and we assessed the activity of gamma-glutamyl transferase (GGT) in hind paw joint homogenate. The experiments included healthy animals, arthritic animals without treatment, and arthritic animals with administration of glucomannan (GM-AA) in the oral daily dose of 15 mg/kg b.w. and of IMG (IMG-AA) in the oral daily dose of 2 mg/kg b.w. The progress of AA was manifested by all parameters monitored. Both substances had beneficial effects on HPV, TBARS levels, GGT activity, and TAS levels. For cytokine assessment, only IMG-AA samples were selected, considering the significant HPV improvement accompanied with the observed anti-oxidant action. IMG administration had a positive immunomodulating effect on all cytokine plasma levels measured, changed markedly due to arthritis progression. Thus, IMG may be considered as a candidate for combinatorial therapy of rheumatoid arthritis.
Adams DS Pero SC Petro JB Nathans R Mackin WM Wakshull E (1997) PGG-Glucan activates NF-kappaB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. J Leukoc Biol62: 865–873.
2.
Bauerová K Bezek S (1999) Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys8: 5–20.
3.
Bauerová K Ponist S Ondrejicková O Komendová D Mihalová D (2006) Association between tissue gamma-glutamyl transferase and clinical markers of adjuvant arthritis model in Lewis rats. Neuro Endocrinol Lett27: 172–175.
4.
Battle J Ha T Li C Della Beffa V Rice P Kalbfleisch J Browder W Williams D (1998) Ligand binding to the 1−3-beta-d-glucan receptor stimulates NF-kappaB activation, but not apoptosis in U937 cells. Biochem Biophys Res Commun249: 499–504.
5.
Bobek P Galbavy S (2001) Effect of pleuran (beta-glucan from Pleurotus ostreatus) on the antioxidant status of the organism and on dimethylhydrazine-induced precancerous lesions in rat colon. Br J Biomed Sci58: 164–168.
6.
Bobek P Nosálová V Cerná S (2001) Effect of pleuran (beta-glucan from Pleurotus ostreatus) in diet or drinking fluid on colitis in rats. Nahrung45: 360–363.
7.
Brown RK Kelly FJ (1996) Peroxides and other products. In: NA Punchard FJ Kelly (eds), Free Radicals, a Practical Approach.Oxford: Oxford University Press, pp. 119–131.
8.
Brown GD Gordon S Dunn W (2001) Immune recognition. A new receptor for beta-glucans. Nature423: 36–37.
9.
Cross GG Jennings HJ Whitfield DM Penney CL Zacharie B Gagnon L (2001) Immunostimulant oxidized beta-glucan conjugates. Int Immunopharmacol1: 539–550.
10.
Czop JK (1986) The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol Immunopathol Res5: 286–296.
11.
Chorvatovicová D Machová E Sandula J Kogan G (1999) Protective effect of the yeast glucomannan against cyclophosphamide –induced mutagenicity. Mutat Res444: 117–122.
12.
Firestein GS Echeverri F Yeo M Zvaifler NJ Green DR (1997) Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A94: 10895–10900.
13.
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature423: 356–361.
14.
Kogan G Pavliak V Masler L (1988) Structural studies of mannans from the cell walls of the pathogenic yeasts Candida albicans serotypes A and B Candida parapsilosis. Carbohydr Res172: 243–253.
15.
Kogan G Sandula J Simkovicova V (1993) Glucomannan from Candida utilis. Folia Microbiol38: 219–224.
16.
Kogan G Staško A Bauerová K Polovka M Šoltés L Brezová V Navarová J Mihalová D (2005) Antioxidant properties of yeast (1→3)-β-d-glucan studied by electron paramagnetic resonance spectroscopy and its activity in the adjuvant arthritis. Carbohydr Polym61: 18–28.
17.
Majtán J Kogan G Kovácová E Bíliková K Simúth J (2005) Stimulation of TNF-α release by fungal cell wall polysaccharides. Z Naturforsch60: 921–926.
18.
Miadoková E Svidová S Vlcková V Dúhová V Nad’ová S Rauko P Kogan G (2006) Diverse biomodulatory effects of glucomannnan from Candida utilis. Toxicology in vitro20: 649–657.
19.
Mihalová D Poništ S Kucharská J Komendová D Bauerová K (2007) Total antioxidant status – systemic marker of oxidative stress in adjuvant arthritis. Chemicke Listy101: 225–226.
20.
Nosál’ová V Bobek P Cerná S Galbavý S Stvrtina S (2001) Effects of pleuran (beta-glucan isolated from Pleurotus ostreatus) on experimental colitis in rats. Physiol Res50: 575–581.
21.
Ondrejickova O Ziegelhoeffer A Gabauer I Sotnikova R Styk J Gibala P Sedlak J Horakova L (1993) Evaluation of ischemia-reperfusion injury by malondialdehyde, glutathione and gamma-glutamyl transpeptidase: lack of specific local effects in diverse parts of the dog heart following acute coronary occlusion. Cardioscience4: 225–230.
22.
Orlowski M Meister A (1970) The gamma-glutamyl cycle: a possible transport system for amino acids. Proc Natl Acad Sci U S A67: 1248–1255.
23.
Prokopová A Kéry V Stanciková M Grimová J Capek P Sandula J Orviský E (1993) Methyl-α-d-mannopyranoside, mannooligosaccharides and yeast mannans inhibit development of rat adjuvant arthritis. J Rheumatology20: 673–677.
24.
Rice PJ Kelley JL Kogan G Ensley HE Kalbfleisch JH Browder IW Williams DL (2002) Human monocyte scavenger receptors are pattern recognition receptors for (1, 3)-beta-d-glucans. J Leukoc Biol72: 140–146.
25.
Rice-Evans C Miller NJ (1994) Total antioxidant status in plasma and body fluids. Methods Enzymol234: 279–293.
26.
Sakurai T Ohno N Yadomae T (1992) Intravenously administered(1→3)-beta-d-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395 augments murine peritoneal macrophage functions in vivo. Chem Pharm Bull (Tokyo)40: 2120–2124.
27.
Sakurai T Ohno N Yadomae T (1996) Effects of fungal beta-glucan and interferon-gama on the secretory functions of murine alveolar macrophages. J Leukoc Biol60: 118–124.
28.
Schepetkin IA Quinn MT (2006) Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol6: 317–333.
29.
Tzianabos AO (2000) Polysaccharide immunomodulators as therapeutic agents: structural aspects and biological function. Clin Microbiol Rev13: 523–533.
30.
Vannier E Miller MC Dinarello CA (1992) Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukon1 production but up regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A89: 4076–4080.
31.
Vlcková V Dúhova V Svidová S Farkassová A Kamasová S Vlcek D Kogan G Rauko P Miadoková E (2004) Antigenotoxic potential of glucomannan on four model test systems. Cell Biol Toxicol20: 325–332.
32.
Waage A Brandtzaeg P Espevik T Halstensen A (1991) Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am5: 781–791.
33.
Wakshull E Brunke-Reese D Lindermuth J Fisette L Nathans RS Crowley JJ Tufts JC Zimmerman J Mackin W Adams DS (1999) PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology41: 89–107.
